Verrica Pharmaceuticals - VRCA Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Verrica Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" VRCA shares.
View VRCA analyst ratings or view top-rated stocks.

4 Wall Street analysts have issued 1 year target prices for Verrica Pharmaceuticals' shares. Their VRCA share price forecasts range from $10.00 to $11.00. On average, they anticipate the company's share price to reach $10.67 in the next twelve months. This suggests a possible upside of 64.1% from the stock's current price.
View analysts price targets for VRCA or view top-rated stocks among Wall Street analysts.

Verrica Pharmaceuticals' stock was trading at $2.75 at the start of the year. Since then, VRCA stock has increased by 136.4% and is now trading at $6.50.
View the best growth stocks for 2023 here.

Verrica Pharmaceuticals saw a increase in short interest in the month of March. As of March 15th, there was short interest totaling 301,600 shares, an increase of 24.8% from the February 28th total of 241,600 shares. Based on an average trading volume of 180,200 shares, the short-interest ratio is currently 1.7 days. Approximately 1.2% of the company's shares are short sold.
View Verrica Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, May 8th 2023.
View our VRCA earnings forecast.

Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) posted its quarterly earnings data on Monday, March, 6th. The company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.19) by $0.05. The company had revenue of $0.07 million for the quarter. Verrica Pharmaceuticals had a negative net margin of 271.11% and a negative trailing twelve-month return on equity of 70.83%.

Based on aggregate information from My MarketBeat watchlists, some companies that other Verrica Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Novan (NOVN), Zosano Pharma (ZSAN), Bionano Genomics (BNGO), CBL & Associates Properties (CBL), Gran Tierra Energy (GTE), Pennsylvania Real Estate Investment Trust (PEI), Organigram (OGI) and Aeterna Zentaris (AEZS).

(VRCA) raised $75 million in an initial public offering on Friday, June 15th 2018. The company issued 5,000,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch, Jefferies and Cowen served as the underwriters for the IPO.

Verrica Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRCA."

Verrica Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include BML Capital Management LLC (2.70%), Millennium Management LLC (0.50%), Geode Capital Management LLC (0.40%), Renaissance Technologies LLC (0.38%), Conning Inc. (0.31%) and Fosun International Ltd (0.31%). Insiders that own company stock include A Brian Davis, Christopher G Hayes, Craig Ballaron, John A Stalfort III, Paul B Manning, Paul B Manning, Perceptive Advisors Llc and Ted White.
View institutional ownership trends.

Shares of VRCA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VRCA stock can currently be purchased for approximately $6.50.

Verrica Pharmaceuticals (NASDAQ:VRCA) has a market capitalization of $272.03 million and generates $9.03 million in revenue each year. The company earns $-24,490,000.00 in net income (profit) each year or ($0.82) on an earnings per share basis.

Verrica Pharmaceuticals' mailing address is 10 NORTH HIGH STREET SUITE 200, WEST CHESTER PA, 19380. The official website for the company is www.verrica.com. The company can be reached via phone at (434) 453-3300 or via email at info@verrica.com.